US 11,883,372 B2
Pharmaceutical composition
Stuart Corr, Warrington (GB); and Timothy James Noakes, Flintshire (GB)
Assigned to MEXICHEM FLUOR S.A. DE C.V., San Luis Potosi S.L.P. (MX)
Filed by MEXICHEM FLUOR S.A. DE C.V., San Luis Potosi S.L.P. (MX)
Filed on Mar. 15, 2022, as Appl. No. 17/694,972.
Application 17/694,972 is a continuation of application No. 16/882,979, filed on May 26, 2020, granted, now 11,311,502.
Application 16/882,979 is a continuation of application No. 16/334,144, granted, now 10,792,256, issued on Oct. 6, 2020, previously published as PCT/GB2017/052764, filed on Sep. 18, 2017.
Claims priority of application No. 1615914 (GB), filed on Sep. 19, 2016; and application No. 1620517 (GB), filed on Dec. 2, 2016.
Prior Publication US 2022/0202746 A1, Jun. 30, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/137 (2006.01); A61K 9/00 (2006.01); A61K 9/12 (2006.01); A61K 31/439 (2006.01); A61K 31/573 (2006.01); A61K 47/14 (2017.01); A61K 47/24 (2006.01); A61K 47/32 (2006.01); A61K 31/56 (2006.01); A61K 45/06 (2006.01); A61P 11/00 (2006.01)
CPC A61K 31/137 (2013.01) [A61K 9/008 (2013.01); A61K 9/0078 (2013.01); A61K 9/124 (2013.01); A61K 31/439 (2013.01); A61K 31/56 (2013.01); A61K 31/573 (2013.01); A61K 45/06 (2013.01); A61K 47/14 (2013.01); A61K 47/24 (2013.01); A61K 47/32 (2013.01); A61P 11/00 (2018.01)] 20 Claims
 
1. A pharmaceutical composition comprising:
a drug component consisting of salmeterol xinafoate and fluticasone propionate, and
(ii) a propellant component at least 90 wt % of which is 1,1-difluoroethane (HFA-152a),
wherein the drug component is the sole drug component in the pharmaceutical composition, and
wherein the pharmaceutical composition is free of (i) polyvinylpyrrolidone, (ii) polyethylene glycol, (iii) polymers having amide and/or carboxylic acid ester repeating structural units.